New drug cocktail targets Hard-to-Treat bile duct cancer

NCT ID NCT07670273

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—as a first treatment for people with advanced or metastatic biliary tract cancer that has HER2 markers. The study aims to see how well the drugs shrink tumors and control the disease. About 70 adults with this type of cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab rezetecan, adebrelimab, and lenvatinib
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with advanced biliary tract cancer that has HER2 markers.
What could go wrong: This is a small, early-phase (Phase II) study with only 70 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer biliary tract neoplasm Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT NEOPLASMS IMMUNOTHERAPY

Contacts and locations

Locations

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, 100730
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.